(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of 295.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Citius Pharmaceuticals's revenue in 2026 is $3,944,111.On average, 4 Wall Street analysts forecast CTXR's revenue for 2026 to be $1,456,660,645, with the lowest CTXR revenue forecast at $1,082,258,268, and the highest CTXR revenue forecast at $1,839,454,182. On average, 4 Wall Street analysts forecast CTXR's revenue for 2027 to be $3,606,184,975, with the lowest CTXR revenue forecast at $3,152,391,036, and the highest CTXR revenue forecast at $4,047,000,587.
In 2028, CTXR is forecast to generate $5,419,346,855 in revenue, with the lowest revenue forecast at $4,027,980,624 and the highest revenue forecast at $6,841,816,320.